Comparing antihypertensive effect and plasma ciclosporin concentration between amlodipine and valsartan regimens in hypertensive renal transplant patients receiving ciclosporin therapy

American Journal of Cardiovascular Drugs

Volumn 11, Issue 6, 2011, Pages 401-409

  Cai, Jingjing ^a   Huang, Zhijun ^a   Yang, Guoping ^a   Cheng, Ke ^a   Ye, Qifa ^a   Ming, Yingzi ^a   Zuo, Xiaocong ^a   Zhou, Peipei ^b   Yuan, Hong ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Department of Cardiology   (United States)

Author keywords

Amlodipine; Genetic Polymorphism; Hypertension; Renal Transplant.

Indexed keywords

AMLODIPINE; CYCLOSPORIN A; CYTOCHROME P450 3A5; METOPROLOL; MULTIDRUG RESISTANCE PROTEIN 1; VALSARTAN;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; GRAFT REJECTION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

ADULT; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROSPECTIVE STUDIES; TETRAZOLES; VALINE;

EID: 83055178363     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11593800-000000000-00000     Document Type: Article

References (43)

1. Morales JM, Andres A, Rengel M, et al. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant 2001; 16 Suppl. 1: 121-4 (Pubitemid 32492523)
2. Morales JM, Dominguez-Gil B. Cardiovascular risk profile with the new immunosuppressive combinations after renal transplantation. J Hypertens 2005 Sep; 23 (9): 1609-16 (Pubitemid 41233417)
3. Hricik DE, Chareandee C, Knauss TC, et al. Hypertension after pancreaskidney transplantation: Role of bladder versus enteric pancreatic drainage. Transplantation 2000 Aug 15; 70 (3): 494-6 (Pubitemid 30641506)
4. Sander M, Lyson T, Thomas GD, et al. Sympathetic neural mechanisms of cyclosporine-induced hypertension.AmJ Hypertens 1996Nov; 9 (11): 121S-38S (Pubitemid 26383507)
5. Akioka K, Takahara S, Ichikawa S, et al. Factors predicting long-term graft urvival after kidney transplantation: multicenter study in Japan. World J Surg 2005 Feb; 29 (2): 249-56 (Pubitemid 40576479)
6. Midtvedt K, Hartmann A. Hypertension after kidney transplantation: Are treatment guidelines emerging? Nephrol Dial Transplant 2002 Jul; 17 (7): 1166-9 (Pubitemid 34812058)
7. Cross NB, Webster AC, Masson P, et al. Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials. Transplantation 2009 Jul 15; 88 (1): 7-18
8. Morris RG, Russ GR, Cervelli MJ, et al. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit 2002 Aug; 24 (4): 479-86 (Pubitemid 34857899)
9. Caforio AL, Tona F, Piaserico S, et al. C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients. Transpl Int 2005 Jan; 18 (1): 116-24 (Pubitemid 41742955)
10. Pescovitz MD, Barbeito R. Two-hour post-dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts. Clin Transplant 2002 Oct; 16 (5): 378-82
11. Julien J, Farge D, Guillemain R, et al. Arterial hypertension in heart transplant recipients [French]. Presse Med 1990 Jan 6-13; 19 (1): 26-9
12. Pagnin E, Giacon B, Zaghetto F, et al. Arterial hypertension and oxidative stress induced by cyclosporine: Effect of carvedilol [Italian]. Ann Ital Med Int 2001 Apr-Jun; 16 (2): 101-5
13. Rossi SJ, Schroeder TJ, Hariharan S, et al. Prevention and management of the adverse effects associated with immunosuppressive therapy. Drug Saf 1993 Aug; 9 (2): 104-31 (Pubitemid 23243522)
14. Bhatnagar V, Garcia EP, O'Connor DT, et al. CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African- American men and women with early hypertensive renal disease. Am J Nephrol 2009 Nov 12; 31 (2): 95-103
15. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet 2010 Mar 1; 49 (3): 141-75
16. Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs 2004; 4 (5): 281-97 (Pubitemid 39429835)
17. Coto E, Tavira B. Pharmacogenetics of calcineurin inhibitors in renal transplantation. Transplantation 2009 Aug 15; 88 (3 Suppl.): S62-7
18. Dorababu M, Nishimura A, Prabha T, et al. Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. Biomed Pharmacother 2009 Nov; 63 (9): 697-702
19. Zhang X, Liu ZH, Zheng JM, et al. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stages after renal transplantation. Clin Transplant 2005 Oct; 19 (5): 638-43 (Pubitemid 41341696)
20. Wei-lin W, Jing J, Shu-sen Z, et al. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl 2006 May; 12 (5): 775-80
21. Ruggenenti P, Perico N, Mosconi L, et al. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 1993 Mar; 43 (3): 706-11 (Pubitemid 23071956)
22. McCulloch TA, Harper SJ, Donnelly PK, et al. Influence of nifedipine on interstitial fibrosis in renal transplant allografts treated with cyclosporin A. J Clin Pathol 1994 Sep; 47 (9): 839-42
23. Bakris G. Are there effects of renin-angiotensin system antagonists beyond blood pressure control? Am J Cardiol 2010 Jan 4; 105 (1 Suppl.): 21A-9A
24. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin- convertingenzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996 Apr 11; 334 (15): 939-45 (Pubitemid 26114159)
25. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997 Jun 28; 349 (9069): 1857-63
26. Inigo P, Campistol JM, Lario S, et al. Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta(1) plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol 2001 Apr; 12 (4): 822-7 (Pubitemid 32246711)
27. Hillebrand U, Suwelack BM, Loley K, et al. Blood pressure, antihypertensive treatment, and graft survival in kidney transplant patients. Transpl Int 2009 Nov; 22 (11): 1073-80
28. Formica Jr RN, Friedman AL, Lorber MI, et al. A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. Nephrol Dial Transplant 2006 May; 21 (5): 1389-94
29. Pesavento TE, Jones PA, Julian BA, et al. Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: Results of a prospective study. J Am Soc Nephrol 1996 Jun; 7 (6): 831-5 (Pubitemid 27465975)
30. Halimi JM, Giraudeau B, Buchler M, et al. Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: A prospective randomized trial. Clin Transplant 2007 Mar-Apr; 21 (2): 277-84 (Pubitemid 46505739)
31. Cantarovich M, Hiesse C, Lockiec F, et al. Confirmation of the interaction between cyclosporine and the calcium channel blocker nicardipine in renal transplant patients. Clin Nephrol 1987 Oct; 28 (4): 190-3 (Pubitemid 17154326)
32. Rump LC, Oberhauser V, Schwertfeger E, et al. Dihydropyridine calcium antagonists and renal function in hypertensive kidney transplant recipients. J Hypertens 2000 Aug; 18 (8): 1115-9
33. Rahn KH, Barenbrock M, Fritschka E, et al. Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: A randomized trial. Lancet 1999 Oct 23; 354 (9188): 1415-20 (Pubitemid 29494752)
34. Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 2003 Feb 6; 348 (6): 538-49 (Pubitemid 36159890)
35. Kahan BD, Keown P, Levy GA, et al. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther 2002 Mar; 24 (3): 330-50; discussion 29
36. Corea L, Cardoni O, Fogari R, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 1996 Sep; 60 (3): 341-6 (Pubitemid 26354455)
37. Kim KA, Park PW, Park JY. Effect of cytochrome P450 3A5. *3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects. Chirality 2009 May; 21 (5): 485-91
38. Kim KA, Park PW, Lee OJ, et al. Effect of CYP3A5. *3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. Clin Pharmacol Ther 2006 Dec; 80 (6): 646-56
39. Bhatnagar V, Garcia EP, O'Connor DT, et al. CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African- American men and women with early hypertensive renal disease. Am J Nephrol 2010; 31 (2): 95-103
40. Fromm MF. Genetically determined differences in P-glycoprotein function: Implications for disease risk. Toxicology 2002 Dec 27; 181-182; 299-303
41. Schwab M, Eichelbaum M, FrommMF. Genetic polymorphisms of the human MDR1 drug transporter. Ann Rev Pharmacol Toxicol 2003; 43: 285-307 (Pubitemid 37372643)
42. Ameyaw MM, Regateiro F, Li T, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001 Apr; 11 (3): 217-21 (Pubitemid 32319871)
43. Kim KA, Park PW, Park JY. Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. Br J Clin Pharmacol 2007 Jan; 63 (1): 53-8